A comparison of four different α1-blockers in benign prostatic hyperplasia patients with and without diabetes

Scandinavian Journal of Urology and Nephrology

Volumn 38, Issue 5, 2004, Pages 391-395

  Bozlu, Murat ^a   Ulusoy, Ercüment ^a   Çayan, Selahittin ^a   Akbay, Esen ^a   Görür, Sadik ^a   Akbay, Erdem ^a  

^a MERSIN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

1 blockers; Benign prostatic hyperplasia; Diabetes mellitus; Lower urinary tract symptoms

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; TAMSULOSIN; TERAZOSIN; DRUG DERIVATIVE; PRAZOSIN; QUINAZOLINE DERIVATIVE; SULFONAMIDE; TERAZOSINE;

ADULT; AGED; ARTICLE; BOTHER SCORE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MICTURITION; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RESIDUAL URINE; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME; UROFLOWMETRY; COHORT ANALYSIS; COMPARATIVE STUDY; FOLLOW UP; HOSPITALIZATION; MICTURITION DISORDER; MIDDLE AGED; PROBABILITY; REFERENCE VALUE; RISK ASSESSMENT; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; COHORT STUDIES; DIABETES MELLITUS; DOXAZOSIN; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PRAZOSIN; PROBABILITY; PROSTATIC HYPERPLASIA; QUINAZOLINES; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TREATMENT OUTCOME; URINATION DISORDERS; URODYNAMICS;

EID: 9244262968     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365590410015678     Document Type: Article

References (17)

1. Chute CG, Pander LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85-9.
2. Jolleys JV, Donovan JL, Nanchahal K, Peters TJ, Abrams P. Urinary symptoms in the community: how bothersome are they? Br J Urol 1994; 74: 551-5.
3. Frimodt-Moller C. Diabetic cystopathy: epidemiology and related disorders. Ann Intern Med 1980; 92: 318-21.
4. Ueda T, Yoshimura N, Yoshida O. Diabetic cystopathy: relationship to autonomic neuropathy detected by sympathetic skin response. J Urol 1997; 157: 580-4.
5. Bourke JB, Griffin JP. Diabetes mellitus in patients with benign prostatic hyperplasia. Br Med J 1968; 4: 492-3.
6. Glynn RJ, Campion EW, Bouchard GR. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 1985; 121: 78-90.
7. Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep 2001; 2: 297-301.
8. Chapple CR. Pharmacotherapy for benign prostatic hyperplasia-the potential for 1α-adrenoceptor subtype-specific blockade. Br J Urol 1998; 81 (Suppl 1): 34-47.
9. Michel MC, Schafers F, Goepel M. α-Blockers and lower urinary tract function: more than smooth muscle relaxation? BJU Int 2000; 86 (Suppl 2): 23-30.
10. Roehrborn CG, Bartsch G, Kirby R, Andriole G, Boyle P, de la Rosette J, et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 2001; 58: 642-50.
11. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effects of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000; 163: 1725-9.
12. Bozlu M, Doruk E, Akbay E, Çayan S, Acar D, Kanik EA. Effect of administration mode (patient vs physician) and patient's educational level on the Turkish version of the International Prostate Symptom Score. Int J Urol 2002; 9: 417-21.
13. Djavan B, Nickel JC, de la Rosette J, Abrams P. The urologist view of BPH progression: results of an international survey. Eur Urol 2002; 41: 490-6.
14. Denis L, McConnell J, Yoshida O, Khoury S, Abram P, Barry M, et al. Recommendations of the International Scientific Committee: the evaluation and treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction. In: Denis L, Griffiths K, Khoury S, Cockett ATK, McConnell J, Chatelain C, et al., editors. Proc 4th Int Consultation on Benign Prostatic Hyperplasia (BPH). Plymouth, UK: Plymbridge Distributors, 1998: pp. 669-83.
15. Chapple CR. Selective α1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996; 29: 129-44.
16. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13.
17. Debruyne FMJ. Alpha blockers: are all created equal? Urology 2000; 56 (Suppl 5A): 20-2.